Pipeline

AD 100

Alzheimer´s disease

• Small molecule oral QPCT/L inhibitors with good blood-brain barrier penetration
• Inhibit production of N3pE amyloid (pGlu-Abeta): neurotoxic, glutaminylated, soluble Abeta peptides
• Significant effects of lead candidate varoglutamstat on working memory, synaptic function & CSF biomarkers after 12w treatment in early AD patients (SAPHIR Phase 2a)